Dr. Oetjen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
University of MichiganResidency, Internal Medicine, 2011 - 2014
University of Michigan Medical SchoolClass of 2011
Certifications & Licensure
MI State Medical License 2011 - 2027
MO State Medical License 2018 - 2025
DC State Medical License 2015 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial Start of enrollment: 2015 Jul 02
- Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) Start of enrollment: 2015 Aug 18
- Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2016 Dec 16
Publications & Presentations
PubMed
- 217 citationsThe distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, Christopher S. Hourigan, Karolyn A. Oetjen
Cancer. 2019-05-01 - 46 citationsPembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.Meghali Goswami, Gege Gui, Laura W Dillon, Katherine E Lindblad, Julie Thompson
Journal for Immunotherapy of Cancer. 2022-01-01 - 462 citationsInfluencing Receptor−Ligand Binding Mechanisms with Multivalent Ligand ArchitectureJason E. Gestwicki, Christopher W. Cairo, Laura E. Strong, Karolyn A. Oetjen, Laura L. Kiessling
Journal of the American Chemical Society. 2002-11-22
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
